Published in Hepatitis Weekly, July 18th, 2005
According to recent research from Italy, "thalidomide, an antiangiogenic agent, does not have a good therapeutic effect for advanced hepatocellular carcinoma when used alone. Megestrol and interleukin-2 have been proposed as a palliative treatment for hepatocellular carcinoma. We assessed the effectiveness/safety of a combined therapy with thalidomide + megestrol + interleukin-2 in cirrhotic patients with advanced hepatocellular carcinoma."
"Nine cirrhotic patients...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.